Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Lukang Pharmaceutical Co's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was ¥80 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥205 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Shandong Lukang Pharmaceutical Co's annualizedROC % for the quarter that ended in Mar. 2026 was 5.42%.
Shandong Lukang Pharmaceutical Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.06%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Shandong Lukang Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.53%.
Shandong Lukang Pharmaceutical Co (SHSE:600789) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Shandong Lukang Pharmaceutical Co's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Lukang Pharmaceutical Co EBIT Related Terms
Shandong Lukang Pharmaceutical Co EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Lukang Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Lukang Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Lukang Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shandong Lukang Pharmaceutical Co's EV-to-EBIT falls into.
Shandong Lukang Pharmaceutical Co EBIT Calculation
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥205 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Lukang Pharmaceutical Co (SHSE:600789) has a EBIT of ¥205 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Lukang Pharmaceutical Co.
Is Shandong Lukang Pharmaceutical Co's EBIT too high?
Shandong Lukang Pharmaceutical Co's current EBIT is ¥205 Mil. Overall, Shandong Lukang Pharmaceutical Co has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shandong Lukang Pharmaceutical Co's EBIT compare to ZTS and UTHR?
Shandong Lukang Pharmaceutical Co's EBIT of ¥205 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Lukang Pharmaceutical Co. Shandong Lukang Pharmaceutical Co's current EBIT is ¥205 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Lukang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Lukang Pharmaceutical Co (SHSE:600789) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.55, compared to a current price of ¥7.18 — trading 4.9% below its estimated fair value. The current EBIT is ¥205 Mil. Shandong Lukang Pharmaceutical Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shandong Lukang Pharmaceutical Co (SHSE:600789), the current EBIT is ¥205 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Lukang Pharmaceutical Co (SHSE:600789) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Lukang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.18 is trading 4.9% below its estimated GF Value™ of ¥7.55.
GuruFocus considers Shandong Lukang Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600789:
EBIT: ¥205 Mil
GF Value™: ¥7.55 vs. price of ¥7.18 (4.9% below fair value)
No single metric tells the full story. See the SHSE:600789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Lukang Pharmaceutical Co Business Description
Shandong Lukang Pharmaceutical Co Ltd is a bio-pharmaceuticals company. It is engaged in manufacturing antibiotics, semi-synthetic antibiotics for human use, bio-pharmaceuticals for veterinary and agriculture use, intermediates, resins, starches, glucose and amino acids.
67GF Score
Get the complete analysis for SHSE:600789
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600789 has been successfully added to your 
